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Abstract
© 2017, Kowsar Corp. Background: The natural history of chronic hepatitis B (CHB) infection is
divided into different phases including immune tolerance (IT), immune clearance (or immune
active [IA]), inactive carrier (IC), and reactivation. Despite utilizing high-throughput data, the
distinct  immunological  mechanisms  of  these  phases  have  been  insufficiently  investigated.
Objectives: The aim of the present study was to determine candidate disease-associated genes
and significantly altered biological processes for each phase of CHB infection. Methods: The
gene expression profiles of 83 CHB patients (22 IT, 50 IA, and 11 IC phases) were obtained from
gene expression  omnibus  (GEO dataset:  GSE65359)  and  analyzed  by  bioinformatics  tools.
Several plugins of Cytoscape software were used to construct protein-protein interaction (PPI)
networks and measure their topological properties. Subsequently, functional annotation and
signaling pathway enrichment were carried out using the database for annotation, visualization
and integrated discovery (DAVID)  and Kyoto encyclopedia  of  genes and genomes (KEGG).
Results: 449 and 452 deregulated genes were identified in IT-IA and IA-IC patients, respectively.
Gene ontology and KEGG pathway analyses showed that several immune response-associated
genes and signaling pathways (i.e. cytokine-cytokine receptor interaction, chemokine signaling
pathway  and  T  cell  receptor  signalling  pathway)  were  upregulated  in  the  IA  phase,  but
downregulated in the IC phase. The LCK (encoding a tyrosine kinase) was determined as the
most  important  hub  gene  of  both  constructed  PPI  networks.  Furthermore,  other  immune
response-associated genes such as  CXCR3,  VCAN,  MYC,  and STAT1 were found to  be the
important hub genes in clinical  phases of  CHB. Conclusions:  The immune response-related
pathways were found to be up and downregulated in the immune clearance phase and inactive
carrier phase of CHB, respectively. The LCK hub gene might help the pathogenesis of different
phases of CHB and serve as a therapeutic target for the treatment of hepatitis B virus.
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